Amgen Inc ((AMGN)), AstraZeneca ((AZN)), AstraZeneca plc ((GB:AZN)), AstraZeneca ((DE:ZEGA)), AstraZeneca plc US ((AZNCF)) announced an update on their ongoing clinical study.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
AstraZeneca and Amgen are currently recruiting participants for a Phase III clinical study titled A Randomised, Double-blind, Placebo-controlled, Parallel Group, Multicentre, Phase III Study to Evaluate the Efficacy and Safety of Tezepelumab in Adult Participants With Moderate to Very Severe Chronic Obstructive Pulmonary Disease. The study aims to assess the safety and efficacy of Tezepelumab in adults with moderate to very severe COPD who are already on inhaled maintenance therapy and have experienced recent exacerbations.
The intervention being tested is Tezepelumab, a biological treatment administered via subcutaneous injection. The study involves two different doses of Tezepelumab and a matching placebo, with the goal of reducing COPD exacerbations.
This interventional study is designed with a randomized, parallel assignment model and employs quadruple masking to ensure unbiased results. The primary purpose of the study is treatment-focused, aiming to provide new insights into COPD management.
The study officially started on March 18, 2025, with the latest update submitted on July 22, 2025. These dates are crucial as they mark the progression of the study and its current recruiting status.
The outcome of this study could significantly impact the market, potentially boosting investor confidence in AstraZeneca and Amgen if results show positive efficacy and safety of Tezepelumab. This development is particularly relevant in the competitive landscape of COPD treatments, where advancements can lead to shifts in market dynamics.
The study is ongoing, with further details available on the ClinicalTrials portal.